Minodronic Acid

- Mar 16, 2019-

Minodronic acid is a third-generation nitrogen-containing heterocyclic bisphosphonate. This product is from Japan Ono Pharmaceutical Co., Ltd. and Japan Astellas (April 2005, Yamauchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., new company name Co-developed for Astellas Pharmaceutical Co., Ltd., submitted to the Japanese Ministry of Health and Welfare in July 2006, and was approved for the first time on January 21, 2009. The trade names are Recalbon® (Ogano Pharmaceuticals) and Bonoteo® (Astellas Pharmaceuticals). Minodronic acid is a novel heterocyclic bisphosphonate compound. The main intermediate is Ethyl trans-4-oxo-2-butenoate CAS 2960-66-9 for the treatment of osteoporosis and osteoporosis. Hyperemia caused by malignant tumors inhibits bone resorption of osteoclasts and inhibits bone turnover by inhibiting the activity of pyrophosphate farnesyl ester (FPP) synthase in osteoclasts, thereby preventing osteoporosis. The comparative advantage of the drug is as follows: compared with the currently used bisphosphonate in clinical practice, its activity of inhibiting bone resorption is 2 times higher than that of inkadiphosphonate and 10 times that of sodium alendronate. 100 times more than disodium minophosphonate, and the incidence of adverse reactions of digestive tract is less than that of existing bisphosphonates. The product has low cost and high profit. Can be selected as a first-line variety developed by enterprises